Accelerated ART Initiation for PWHIV Who Are Out of Care
Conditions: HIV Infections; ART; Noncompliance, Patient Interventions: Other: The Accelerate model of care; Drug: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg Sponsors: University of Missouri-Columbia; Gilead Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy
March 5, 2024 -- The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants
Conditions: Healthy Adult Participants Interventions: Drug: ACC017 tablets; Drug: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets Sponsors: Jiangsu Aidea Pharmaceutical Co., Ltd; Chengdu Aidea Pharmaceutical Technology Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
Conditions: Prevention Interventions: Drug: Cabotegravir Tablets, for oral use.; Drug: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.; Drug: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use; Procedure: Rectal Biopsies Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
Conditions: HIV Infections Interventions: Drug: APRETUDE (cabotegravir) 600 mg\3 mL; Drug: DAPIRING (Dapivirine) 25mg Vaginal Ring; Drug: tenofovir disoproxil and emtricitabine; Drug: Tenofovir Disoproxil, Lamuvidine and Dolutegravir Sponsors: Africa Health Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-na ïve People Living With HIV-1 Infection
Conditions: HIV-1-infection Interventions: Drug: Doravirine + tenofovir DF + lamivudine; Drug: Dolutegravir + tenofovir DF + lamivudine or emtricitabine Sponsors: ANRS, Emerging Infectious Diseases; MSD France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
Conditions: HIV Infections Interventions: Drug: Cabotegravir Injection [Apretude]; Drug: Tenofovir disoproxil fumarate / emtricitabine (or lamivudine) Sponsors: University of Witwatersrand, South Africa; ViiV Healthcare; Bill and Melinda Gates Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa
Conditions: HIV Interventions: Drug: Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA); Drug: Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) Sponsors: MRC/UVRI and LSHTM Uganda Research Unit; King ' s College London; London School of Hygiene and Tropical Medicine; Africa Health Research Institute; Wits Health Consortium (Pty) Ltd; University College, London; Ministry of Health, Uganda; Desmond Tutu HIV Foundation; Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN-103)
Conditions: Pre-Exposure Prophylaxis of HIV Infection Interventions: Drug: Lenacapavir Injection; Drug: Lenacapavir Tablet; Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF) Sponsors: Gilead Sciences; HIV Prevention Trials Network; National Institute on Drug Abuse (NIDA); National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN-102)
Conditions: Pre-Exposure Prophylaxis of HIV Infection Interventions: Drug: Lenacapavir Tablet; Drug: Lenacapavir Injection; Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Sponsors: Gilead Sciences; HIV Prevention Trials Network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)
Conditions: Hiv Prevention; Pre-Exposure Prophylaxis (PrEP) Intervention: Drug: Truvada Sponsor: CAN Community Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
